Precede Biosciences
Rehan Verjee is a seasoned executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Co-founder and CEO of Precede Biosciences since September 2021, Verjee's focus is on advancing precision medicine through innovative technology. Alongside this role, Verjee is a Strategic Advisor at Formation Bio, a Board Member at Tyra Biosciences and MassBio, and has held significant positions at EMD Serono, including President and Global Head of Innovative Medicines Franchises. Previous experience includes serving as EVP, Chief Marketing and Strategy Officer at Merck KGaA and Managing Director for Canada at EMD Serono. Verjee's educational background includes an MBioch in Molecular and Cellular Biochemistry from the University of Oxford.
Precede Biosciences
1 followers
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.